A Phase III Study to Evaluate Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women With Receptor (ER and/or PgR) Positive Tumors.

Trial Profile

A Phase III Study to Evaluate Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women With Receptor (ER and/or PgR) Positive Tumors.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Letrozole (Primary) ; Tamoxifen
  • Indications Early breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms BIG 1-98
  • Most Recent Events

    • 10 Apr 2017 Results (n=7963) assessing effect of cholesterol-lowering medication in combination with endocrine therapy on breast cancer outcomes, published in the Journal of Clinical Oncology.
    • 12 Dec 2015 Results presented at the 38th Annual San Antonio Breast Cancer Symposium
    • 04 Jun 2013 Analysis assessing efficacy outcomes according to histological subtypes of breast cancer presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top